loncastuximab tesirine + ibrutinib

Loncastuximab tesirine + ibrutinib is a combination of an antibody-drug conjugate (ADC) and a small-molecule inhibitor, investigated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Loncastuximab tesirine is a humanized anti-CD19 monoclonal antibody conjugated via a valine-alanine cleavable linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin, targeting CD19-positive B-cells and causing DNA interstrand cross-linking and cell death upon internalization. Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), a crucial component of the B-cell receptor signaling pathway, which regulates B-cell proliferation and survival. Together, these drugs act synergistically to enhance anti-tumor activity in B-cell malignancies[1][3][7][9].